- Home
- CRVS vs AQST Comparison
CRVS vs AQST Comparison
Compare CRVS & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- AQST
- Stock Information
- Founded
- CRVS 2014
- AQST 2004
- Country
- CRVS United States
- AQST United States
- Employees
- CRVS N/A
- AQST N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- CRVS Health Care
- AQST Health Care
- Exchange
- CRVS Nasdaq
- AQST Nasdaq
- Market Cap
- CRVS 257.0M
- AQST 274.4M
- IPO Year
- CRVS 2016
- AQST 2018
- Fundamental
- Price
- CRVS $3.21
- AQST $3.04
- Analyst Decision
- CRVS Strong Buy
- AQST Strong Buy
- Analyst Count
- CRVS 5
- AQST 6
- Target Price
- CRVS $12.63
- AQST $11.17
- AVG Volume (30 Days)
- CRVS 704.3K
- AQST 1.4M
- Earning Date
- CRVS 05-05-2025
- AQST 05-06-2025
- Dividend Yield
- CRVS N/A
- AQST N/A
- EPS Growth
- CRVS N/A
- AQST N/A
- EPS
- CRVS N/A
- AQST N/A
- Revenue
- CRVS N/A
- AQST $57,561,000.00
- Revenue This Year
- CRVS N/A
- AQST N/A
- Revenue Next Year
- CRVS N/A
- AQST $39.51
- P/E Ratio
- CRVS N/A
- AQST N/A
- Revenue Growth
- CRVS N/A
- AQST 13.79
- 52 Week Low
- CRVS $1.30
- AQST $2.24
- 52 Week High
- CRVS $10.00
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- CRVS 29.29
- AQST 51.97
- Support Level
- CRVS $3.06
- AQST $3.05
- Resistance Level
- CRVS $3.45
- AQST $3.24
- Average True Range (ATR)
- CRVS 0.37
- AQST 0.19
- MACD
- CRVS -0.10
- AQST 0.01
- Stochastic Oscillator
- CRVS 8.77
- AQST 48.53
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.